Clinical Trial

Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy

Study acronym: RISE 3
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Summary
The purpose of this study is to determine whether BHV-7000 is effective in the treatment of refractory focal epilepsy.
Protocol Amendment History 4 changes
critical Trial status changed: Recruiting → Active, Not Recruiting 2026-07-02
notable Trial sites reduced: 174 -> 152 locations 2026-07-02
notable Primary completion pushed: 2026-05 -> 2026-10 2026-07-02
minor Completion pushed: 2026-05 -> 2026-10 2026-07-02
Trial Details
NCT Number NCT06309966
Lead Sponsor Biohaven Therapeutics Ltd.
Conditions Focal Epilepsy
Enrollment 390 participants
Start Date 2024-05-13
Primary Completion 2026-10 (estimated)
Study Completion 2026-10 (estimated)
Updated on ClinicalTrials.gov 2026-08-13